Nevertheless, these data also raise the question of whether enhancing circulating ANP concentrations with current antihypertensive agents (neprilysin inhibitors) may have added advantages in patients with hypertensive heart disease caused by volume-dependent hypertension. The gene discussed is MME; the disease is hypertensive heart disease.